StopCraving_12
New Member
"With the recent transition to the Trump administration—whose leader has repeatedly criticized pharmaceutical companies for "getting away with murder" on pricing and specifically targeted the cost of weight loss medications—I have wondered whether the FDA might reverse course under new leadership and side with compounders offering lower-priced alternatives. The FDA's new court filing indicates that the agency is standing firmly with patent holders and the drug approval system that grants market exclusivity"

Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute
by Dennis Crouch Since late 2022, the extraordinary demand for glucagon-like peptide-1 receptor agonists (GLP-1s) like Eli Lilly's tirzepatide (marketed …
patentlyo.com